Integral Biosciences (IBS) is a Delhi-based Indian biotech company, which operates on a hybrid business model. This model enables revenue generation through its services business/ CRO, in parallel with the development of an internal drug discovery pipeline. This model significantly reduces the investment requirements, when compared with biotech companies more broadly, and enables a significant in-house capability to be maintained.
IBS's drug discovery services business was established in 2008 and since that time has continued to expand to serve a wider range of clients across the world. It has a great success record for a company of 60-80 people, delivering from pre-clinical to clinical candidates. IBS can help with various aspects of early drug discovery including:-
Hit to Lead
Back-up Candidate Identification
IBS provides high-quality medicinal chemistry services that efficiently progress drug discovery projects from hit identification through lead generation and optimization, to the nomination of effective drug candidates. Our medicinal chemists have extensive experience in developing drug candidates against a broad range of target disease indications, which has provided us with one of the best track records in the industry.
At IBS, our primary asset is our knowledgeable and creative scientists. Our pharmaceutically trained researchers draw upon years of experience in early stage drug discovery acquired across a wide range of therapeutic areas and biological targets. Through tractable hit-series identification and productive analogue design and synthesis, we can help you identify and optimise pre-clinical candidates in the area of small molecule drug discovery.
IBS delivers excellence through thoughtful interpretation and rational integration of SAR and PK/ADME results into the design-make-test-analyse cycle. Our medicinal chemistry team is committed to rapidly advancing research programs by providing, fast, flexible and innovative solutions.